An intranasal vaccine combining mutated KRAS peptides with a nanoemulsion adjuvant activated anti-tumor immune responses in the lungs and significantly reduced tumor incidence in a KRAS-mutant lung cancer mouse model.
Significantly reduced tumor incidencein KRAS-mutant lung cancer mice, with persistent Th1/Th17 responses lasting 3 months and reduced immunosuppressive T cells
What the researchers found
Intranasal KRAS peptide vaccine with nanoemulsion adjuvant significantly reduced lung tumor incidence in KRAS-mutant mice by inducing persistent KRAS-specific Th1/Th17 responses and reducing immunosuppressive regulatory T cells.
Why it matters
KRAS mutations account for about 25% of all lung cancers and have been notoriously difficult to target therapeutically. An intranasal peptide vaccine could prevent KRAS-driven tumors from developing or catch them early — particularly valuable for high-risk individuals like former heavy smokers with known KRAS mutations.
The numbers in context
Vaccine used mutated and wild-type KRAS peptides; intranasal delivery; tested in NSCLC animal models.
How the study worked
Intranasal immunization of mice with mutated and wild-type KRAS peptides in nanoemulsion adjuvant. Used inducible mutant KRAS lung tumor mouse model. Assessed immune responses (CD4/CD8 T cells, cytokines, FoxP3+ Tregs) and tumor incidence. Persistence evaluated at 3 months post-vaccination.
Who was studied
Animal models of KRAS-mutant non-small cell lung cancer
What this study cannot tell us
Mouse study — human immune responses to KRAS peptides may differ. The inducible KRAS model is artificial compared to natural tumor development. Immune response persistence beyond 3 months not assessed. The vaccine's effectiveness against established tumors (therapeutic use) was not tested. Optimal dose, schedule, and adjuvant for humans are unknown.
How to read the evidence
Preliminary — single animal study demonstrating proof-of-concept for intranasal KRAS peptide vaccination. Promising immune and tumor prevention data, but far from clinical application.
When this study was published
Published in 2024 in Cell Death & Disease, addressing the challenging target of KRAS-mutant lung cancer through a novel vaccination approach.
The bigger picture
Cancer prevention vaccines represent a paradigm shift from treating cancer to preventing it. This intranasal approach is particularly clever — delivering the vaccine directly to the lung mucosa where KRAS-mutant tumors originate, generating local immune surveillance rather than relying on systemic immunity to reach lung tissue. If translated to humans, it could complement lung cancer screening in high-risk populations.
Questions still open
- Could this KRAS peptide vaccine prevent lung cancer in former smokers with known KRAS mutations?
- Does the vaccine work therapeutically against established KRAS-mutant tumors, or only preventively?
- Would combining this vaccine with checkpoint inhibitors enhance anti-tumor efficacy?
Common questions
Why deliver a cancer vaccine through the nose?
Could a vaccine prevent lung cancer in people?
Read the original research
A novel intranasal peptide vaccine inhibits non-small cell lung cancer with KRAS mutation.
Cancer gene therapy, 31(3), 464-471
Citation
Wang, Su He; Cao, Zhengyi; Farazuddin, Mohammad; Chen, Jesse; Janczak, Katarzyna W; Tang, Shengzhuang; Cannon, Jayme; Baker, James R. (2024). A novel intranasal peptide vaccine inhibits non-small cell lung cancer with KRAS mutation.. Cancer gene therapy, 31(3), 464-471. https://doi.org/10.1038/s41417-023-00717-9